397 related articles for article (PubMed ID: 24813269)
1. Re: Liam Bourke, Stephen Gilbert, Richard Hooper, et al. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial. Eur Urol 2014;65:865-72; Re: Daniel A. Galvão, Nigel Spry, James Denham, et al. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR. Eur Urol 2014;65:856-64; Re: Nancy L. Keating, Pang-Hsiang Liu, A. James O'Malley, Stephen J. Freedland, Matthew R. Smith. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol 2014;65:816-24; Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 2014;65:704-9.
Goonewardene SS; Persad R; Young A; Makar A
Eur Urol; 2014 Sep; 66(3):e51-2. PubMed ID: 24813269
[No Abstract] [Full Text] [Related]
2. Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Schooling CM; Sembajwe G; Agalliu I
Eur Urol; 2013 Sep; 64(3):e59-60. PubMed ID: 23623050
[No Abstract] [Full Text] [Related]
3. Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's letter to the editor Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2013 Sep; 64(3):e61. PubMed ID: 23622775
[No Abstract] [Full Text] [Related]
4. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.
Galvão DA; Spry N; Denham J; Taaffe DR; Cormie P; Joseph D; Lamb DS; Chambers SK; Newton RU
Eur Urol; 2014 May; 65(5):856-64. PubMed ID: 24113319
[TBL] [Abstract][Full Text] [Related]
5. Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time?
Harrison MR; Jones LW
Eur Urol; 2014 May; 65(5):873-4. PubMed ID: 24315708
[No Abstract] [Full Text] [Related]
6. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
Jespersen CG; Nørgaard M; Borre M
Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
[TBL] [Abstract][Full Text] [Related]
7. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial.
Bourke L; Gilbert S; Hooper R; Steed LA; Joshi M; Catto JW; Saxton JM; Rosario DJ
Eur Urol; 2014 May; 65(5):865-72. PubMed ID: 24119318
[TBL] [Abstract][Full Text] [Related]
8. Androgen-deprivation therapy and cardiovascular harm: let's not throw out the baby with the bathwater.
Nguyen PL
Eur Urol; 2014 Apr; 65(4):710-2. PubMed ID: 23498063
[No Abstract] [Full Text] [Related]
9. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
10. Re: Rhonda L. Bitting, Patrick Healy, Daniel J. George, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol 2021;4:948-54.
Guler OC; Isci O; Onal C
Eur Urol Oncol; 2022 Aug; 5(4):477-478. PubMed ID: 35307322
[No Abstract] [Full Text] [Related]
11. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
12. Re: Loren K. Mell, Stephanie L. Pugh, Christopher U. Jones, et al. Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.01.020.
Jung J; Kim JH
Eur Urol; 2023 Sep; 84(3):e73-e74. PubMed ID: 37202316
[No Abstract] [Full Text] [Related]
13. Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial.
Taaffe DR; Newton RU; Spry N; Joseph D; Chambers SK; Gardiner RA; Wall BA; Cormie P; Bolam KA; Galvão DA
Eur Urol; 2017 Aug; 72(2):293-299. PubMed ID: 28249801
[TBL] [Abstract][Full Text] [Related]
14. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.
Meng F; Zhu S; Zhao J; Vados L; Wang L; Zhao Y; Zhao D; Niu Y
BMC Cancer; 2016 Mar; 16():180. PubMed ID: 26940836
[TBL] [Abstract][Full Text] [Related]
15. Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol.
Østergren P; Ragle AM; Jakobsen H; Klausen TW; Vinther A; Sønksen J
BMJ Open; 2016 Jun; 6(6):e011460. PubMed ID: 27357198
[TBL] [Abstract][Full Text] [Related]
16. Improving Physical and Mental Health in Patients with Prostate Cancer Undergoing Androgen Deprivation Therapy: Strategies to Promote and Improve Physical Activity Quality and Quantity.
Toohey K; McKune A; Nahon I; Kavanagh PS; Newton RU; Paterson C
Semin Oncol Nurs; 2020 Aug; 36(4):151051. PubMed ID: 32682582
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.
Galvão DA; Spry N; Taaffe DR; Denham J; Joseph D; Lamb DS; Levin G; Duchesne G; Newton RU
BMC Cancer; 2009 Dec; 9():419. PubMed ID: 19951446
[TBL] [Abstract][Full Text] [Related]
18. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
J Clin Oncol; 2017 Nov; 35(32):3697-3705. PubMed ID: 28968166
[TBL] [Abstract][Full Text] [Related]
19. Re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol suppl 2010;9:675-91.
Langley RE; Price P; Abel PD
Eur Urol; 2011 Apr; 59(4):e24-5; author reply e26. PubMed ID: 21255905
[No Abstract] [Full Text] [Related]
20. Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
Baguley BJ; Skinner TL; Leveritt MD; Wright OR
BMC Cancer; 2017 Jan; 17(1):1. PubMed ID: 28049525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
